Abstract 1337
Background
Standard guidelines recommend mutation testing for KRAS, NRAS and BRAF in MCRC. POG at BC Cancer is an investigational project that performs WGTA to identify potential hypothetical actionable biomarkers. We aimed to determine its clinical significance compared to standard sequencing panels by analyzing the prevalence of actionable variants and their impact on treatment decisions.
Methods
We analyzed 69 POG MCRC patients (pts) and summarized their WGTA results to identify germline and somatic coding variants, copy number alterations, structural alterations and gene expression outliers. Actionable items were defined as variants that could direct therapy with an investigational or approved agent, and were classified as either standard (found in local sequencing panel- BC Oncopanel) or expanded (not in Oncopanel).
Results
74% of pts received 2 or more prior lines of chemotherapy. 1 pt died before biopsy was made available and 1 pt had an unsuccessful biopsy. Remaining analysis of 67 pts revealed 49 (73%) pts with actionable alterations, of which 43% consisted of mutation changes, 40% expression changes, 14% copy number variants, and 3% high mutational burden or HRD. Most common standard alterations (54%) were mutations in TP53, KRAS, BRAF, PIK3CA and most common expanded items (46%) were high expression of FGFR1/3, FLT1/3, and VEGFA/B. Among these, 13 (27%) pts had alterations that led to standard chemotherapy or anti-EGFR based treatment, and 7 (14%) pts had a variant that resulted in non-standard therapies. Of those, only irbesartan, targeting the FOS-JUN pathway, resulted in a meaningful response duration of 28 months, while the remaining had an average PFS of 1.7 month. 29 (59%) pts did not receive therapy outlined in POG analysis due to lack of access for the target drug (n = 15), poor performance status (n = 7), and patient or physician preference (n = 7).
Conclusions
WGTA in MCRC provided additional understanding of tumor biology, with high rates of expression changes not otherwise captured in standard sequencing panel. However, at the present time, there is limited additional clinical therapeutic benefit in comparison. Future development is needed and ongoing.
Clinical trial identification
Legal entity responsible for the study
BC Cancer.
Funding
BC Cancer Foundation.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4784 - Tranilast inhibits TGF-beta-induced EMT and invasion/metastasis via the suppression of Smad4 in lung cancer cell lines.
Presenter: Koji Takahashi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
767 - Integrin beta-like 1 overexpression stimulates invasiveness of ovarian cancer cells in vitro
Presenter: Alexander Cortez
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
938 - MiR-449a suppresses endometrial cancer invasion and metastasis by targeting NDRG1
Presenter: Lihua Qiu
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4866 - Cancer-associated fibroblasts-derived VEGFA mediates the migration of gastric cancer cells through VEGFR1
Presenter: xiaoxun Wang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4934 - Risk prediction of metastasis through study of circulating tumor cells
Presenter: Panagiotis Apostolou
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3289 - First step to metastasis: miRNAome abnormalities impair cell-cell adhesion and facilitate detachment of breast cancer cells
Presenter: Volodymyr Halytskiy
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4110 - Extracellular matrix of normal brain tissue is affected by temozolomide during anti-glioblastoma treatment
Presenter: Alexandra Tsidulko
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1526 - Study of the activation of TLR receptors in neurospheres from glioblastoma cells in vitro
Presenter: David Albert Bellver
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4862 - 5-Fluorouracil induced up-regulation of exosomal PD-L1 causing immunosuppression in gastric cancer patients
Presenter: Zhang Min
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
635 - Thrombocytosis and leukocytosis: are they negative prognostic factors in solid tumours?
Presenter: Filip Kohutek
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract